Spinifex closes Series B with $19M

Australia's Spinifex Pharmaceuticals says its added more than $6 million to its second round, bringing the Series B total to $19 million. GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management, and UniQuest all chipped in with cash, which is being earmarked for a mid-stage study of EMA401 for neuropathic pain. Story